Dampak Pemberian Active Hexose Correlated Compound (AHCC) Terhadap Kadar Cluster Of Differentation 4 (CD4) Pada Pasien Kanker Paru Karsinoma Bukan Sel Kecil Yang Dilakukan Kemoterapi

Abstract

ABSTRACT Background: Lung cancer is one of the cancers with high mortality rates worldwide, making the development of interventions that enhance immune response critical. This study aims to evaluate the effect of Active Hexose Correlated Compound (AHCC) administration on CD4+ levels in patients with Non-Small Cell Lung Cancer (NSCLC) undergoing chemotherapy Methods: This study employed a randomized controlled trial with a double-blind and truly experimental case-control design, conducted at RSUP H. Adam Malik, RS USU, and RS Elisabeth Medan from December 2022 to December 2024. Results: The sample consisted of 50 patients diagnosed with non-small cell lung carcinoma. Data analysis showed no significant difference in CD4+ levels between the AHCC and placebo groups (p > 0.05), although AHCC is hypothesized to have immunomodulatory potential. Most patients were in advanced cancer stages (Stage IV A at 72%). These results indicate that AHCC administration does not significantly increase CD4+ levels during chemotherapy in lung cancer patients; however, further studies with larger samples and longer durations are needed to confirm these findings. Conclusion: This research contributes to knowledge on immune management in lung cancer and the potential therapeutic role of AHCC as a supplementary treatment. Keywords: NSCLC, CD4+, AHCC